Invivyd (IVVD) Operating Leases (2022 - 2026)
Invivyd's (IVVD) quarterly Operating Leases came in at $6.8 million in Q2 2026, up 257.89% on a YoY basis from $1.9 million in Q2 2025, and up 476.27% quarter-over-quarter from $1.2 million in Q4 2025.
Analysis
Invivyd (IVVD) Operating Leases (2022 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Operating Leases for 5 consecutive years, with $6.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Leases rose 257.89% year-over-year to $6.8 million; the trailing twelve-month figure through Jun 2026 stood at $6.8 million (up 257.89% YoY), and the FY2025 full-year result was $1.2 million, down 32.22% from the prior year.
- Operating Leases rose to $6.8 million in Q2 2026 per IVVD's latest filing, from $1.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $6.8 million in Q2 2026 and bottomed at $100000.0 in Q1 2022.
- Historically, Operating Leases has averaged $1.5 million across 5 years, with a median of $1.3 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Operating Leases slumped 76.38% in 2024, then soared 630.59% in 2025.
- Over 5 years, Operating Leases stood at $2.2 million in 2022, then dropped by 20.05% to $1.7 million in 2023, then climbed by 0.58% to $1.7 million in 2024, then slumped by 32.22% to $1.2 million in 2025, then surged by 476.27% to $6.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $6.8 million, $1.2 million, and $1.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.80 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 219,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 927,000.00 |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 432,000.00 |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 100,000.00 |